专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07683033B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease 失效
标题翻译：丝氨酸蛋白酶抑制剂，特别是HCV NS3-NS4A蛋白酶
公开(公告)号：US07683033B2
公开(公告)日：2010-03-23
申请号：US11051977
申请日：2005-02-04
申请人： Kevin M. Cottrell , John J. Court , David D. Deininger , Luc J. Farmer , Janos Pitlik , Robert B. Permi
发明人： Kevin M. Cottrell , John J. Court , David D. Deininger , Luc J. Farmer , Janos Pitlik , Robert B. Permi
IPC分类号： A61K38/07 , A61K39/42
CPC分类号： C07K5/10 , A61K38/00 , A61K38/07 , A61K45/06 , C07K5/0202 , C07K7/02 , C07K14/005 , C12N2770/24222
摘要： The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐或混合物。因此，它们通过干扰丙型肝炎病毒的生命周期起作用，也可用作抗病毒剂。本发明还涉及包含用于离体使用或用于给予HCV感染患者的这些化合物的组合物和制备该化合物的方法。本发明还涉及通过施用包含本发明化合物的组合物来治疗患者HCV感染的方法。本发明还涉及制备这些化合物的方法。

2. 发明申请

US20100330109A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE 有权
标题翻译：丝氨酸蛋白酶特异性HCV NS3-NS4A蛋白的抑制剂
公开(公告)号：US20100330109A1
公开(公告)日：2010-12-30
申请号：US12639162
申请日：2009-12-16
申请人： Kevin M. Cottrell , John J. Court , David D. Deininger , Luc J. Farmer , Janos Pitlik , Robert B. Perni
发明人： Kevin M. Cottrell , John J. Court , David D. Deininger , Luc J. Farmer , Janos Pitlik , Robert B. Perni
IPC分类号： A61K39/00 , C07K5/08 , A61K38/55 , C12N9/99 , A61P31/14 , A61P37/02
CPC分类号： C07K5/10 , A61K38/00 , A61K38/07 , A61K45/06 , C07K5/0202 , C07K7/02 , C07K14/005 , C12N2770/24222
摘要： The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐或混合物。因此，它们通过干扰丙型肝炎病毒的生命周期起作用，也可用作抗病毒剂。本发明还涉及包含用于离体使用或用于给予HCV感染患者的这些化合物的组合物和制备该化合物的方法。本发明还涉及通过施用包含本发明化合物的组合物来治疗患者HCV感染的方法。本发明还涉及制备这些化合物的方法。

3. 发明授权

US07273885B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease 失效
标题翻译：丝氨酸蛋白酶抑制剂，特别是HCV NS3-NS4A蛋白酶
公开(公告)号：US07273885B2
公开(公告)日：2007-09-25
申请号：US10412600
申请日：2003-04-11
申请人： Janos Pitlik , Kevin M. Cottrell , Luc J. Farmer , Robert B. Perni , Lawrence F. Courtney , John H. van Drie , Mark A. Murcko
发明人： Janos Pitlik , Kevin M. Cottrell , Luc J. Farmer , Robert B. Perni , Lawrence F. Courtney , John H. van Drie , Mark A. Murcko
IPC分类号： A61K31/403 , A61K31/435 , C07D209/02 , C07D221/00
CPC分类号： C07D209/42 , C07D209/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D417/12 , C07D471/04 , C07K5/06008 , C07K5/0812 , C07K5/1024 , C07K5/1027
摘要： The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的化合物。因此，它们通过干扰丙型肝炎病毒的生命周期起作用，也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，用于离体使用或给予患有HCV感染的患者。本发明还涉及通过施用包含本发明化合物的组合物来治疗患者HCV感染的方法。本发明还涉及制备这些化合物的方法。

4. 发明申请

US20100173851A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE 审中-公开
标题翻译：丝氨酸蛋白酶特异性HCV NS3-NS4A蛋白的抑制剂
公开(公告)号：US20100173851A1
公开(公告)日：2010-07-08
申请号：US12477581
申请日：2009-06-03
申请人： Janos Pitlik , Kevin M. Cottrell , Luc J. Farmer , Robert B. Perni , Lawrence F. Courtney , John H. van Drie , Mark A. Murcko
发明人： Janos Pitlik , Kevin M. Cottrell , Luc J. Farmer , Robert B. Perni , Lawrence F. Courtney , John H. van Drie , Mark A. Murcko
IPC分类号： A61K38/08 , C07K5/02 , A61P31/14 , A01N43/38 , A01P1/00
CPC分类号： C07D209/42 , C07D209/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D417/12 , C07D471/04 , C07K5/06008 , C07K5/0812 , C07K5/1024 , C07K5/1027
摘要： The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的化合物。因此，它们通过干扰丙型肝炎病毒的生命周期起作用，也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，用于离体使用或给予患有HCV感染的患者。本发明还涉及通过施用包含本发明化合物的组合物来治疗患者HCV感染的方法。本发明还涉及制备这些化合物的方法。

5. 发明授权

US08426359B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease 失效
标题翻译：丝氨酸蛋白酶抑制剂，特别是HCV NS3-NS4A蛋白酶
公开(公告)号：US08426359B2
公开(公告)日：2013-04-23
申请号：US12265125
申请日：2008-11-05
申请人： Kevin M. Cottrell , Robert B. Perni , Janos Pitlik , Wayne C. Schairer
发明人： Kevin M. Cottrell , Robert B. Perni , Janos Pitlik , Wayne C. Schairer
IPC分类号： A61K38/00
CPC分类号： C07K5/10 , C07K7/06
摘要： The present invention relates to compounds of formula I: or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐。因此，它们通过干扰丙型肝炎病毒的生命周期起作用，并且作为抗病毒剂是有用的。本发明还涉及包含用于离体使用或用于给予HCV感染患者的所述化合物的药学上可接受的组合物以及制备该化合物的方法。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗患者HCV感染的方法。

6. 发明申请

US20090291902A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE 失效
标题翻译：丝氨酸蛋白酶特异性HCV NS3-NS4A蛋白的抑制剂
公开(公告)号：US20090291902A1
公开(公告)日：2009-11-26
申请号：US12265125
申请日：2008-11-05
申请人： Kevin M. Cottrell , Robert B. Perni , Janos Pitlik , Wayne C. Schairer
发明人： Kevin M. Cottrell , Robert B. Perni , Janos Pitlik , Wayne C. Schairer
IPC分类号： A61K38/06 , A61K38/07 , C07K5/08 , C07K5/10
CPC分类号： C07K5/10 , C07K7/06
摘要： The present invention relates to compounds of formula I: or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐。因此，它们通过干扰丙型肝炎病毒的生命周期起作用，并且作为抗病毒剂是有用的。本发明还涉及包含用于离体使用或用于给予HCV感染患者的所述化合物的药学上可接受的组合物以及制备该化合物的方法。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗患者HCV感染的方法。

7. 发明申请

US20080125376A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE 有权
标题翻译：丝氨酸蛋白酶特异性HCV NS3-NS4A蛋白的抑制剂
公开(公告)号：US20080125376A1
公开(公告)日：2008-05-29
申请号：US12026705
申请日：2008-02-06
申请人： Kevin M. Cottrell , John Maxwell , Robert B. Perni , Janos Pitlik
发明人： Kevin M. Cottrell , John Maxwell , Robert B. Perni , Janos Pitlik
IPC分类号： A61K38/05 , A61P41/00 , A61P31/12
CPC分类号： C07K5/0804 , A61K31/40 , A61K45/06 , A61K2300/00
摘要： The present invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐。因此，它们通过干扰丙型肝炎病毒的生命周期起作用，并且作为抗病毒剂是有用的。本发明还涉及包含用于离体使用或用于给予HCV感染患者的所述化合物的药学上可接受的组合物以及制备该化合物的方法。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗患者HCV感染的方法。

8. 发明授权

US07109172B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease 有权
标题翻译：丝氨酸蛋白酶抑制剂，特别是HCV NS3-NS4A蛋白酶
公开(公告)号：US07109172B2
公开(公告)日：2006-09-19
申请号：US10893748
申请日：2004-07-16
申请人： Shawn D. Britt , Kevin M. Cottrell , Robert B. Perni , Janos Pitlik
发明人： Shawn D. Britt , Kevin M. Cottrell , Robert B. Perni , Janos Pitlik
IPC分类号： A61K38/00
CPC分类号： C07K7/06
摘要： The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的式I或式Ia化合物或其药学上可接受的盐。因此，它们通过干扰丙型肝炎病毒的生命周期起作用，并且作为抗病毒剂是有用的。本发明还涉及包含用于离体使用或用于给予HCV感染的患者的所述化合物的药学上可接受的组合物和用于制备所述化合物的方法。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗患者HCV感染的方法。

9. 发明授权

US08039623B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease 失效
标题翻译：丝氨酸蛋白酶抑制剂，特别是HCV NS3-NS4A蛋白酶
公开(公告)号：US08039623B2
公开(公告)日：2011-10-18
申请号：US11716248
申请日：2007-03-09
申请人： Kevin M. Cottrell , Robert B. Perni , Janos Pitlik
发明人： Kevin M. Cottrell , Robert B. Perni , Janos Pitlik
IPC分类号： C07D241/02 , A61K31/495
CPC分类号： C07K7/06 , A61K38/08
摘要： The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐或混合物。因此，它们通过干扰丙型肝炎病毒的生命周期起作用，也可用作抗病毒剂。本发明还涉及包含用于离体使用或用于给予HCV感染患者的这些化合物的组合物和制备该化合物的方法。本发明还涉及通过施用包含本发明化合物的组合物来治疗患者HCV感染的方法。本发明还涉及制备这些化合物的方法。

10. 发明授权

US07906550B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease 有权
标题翻译：丝氨酸蛋白酶抑制剂，特别是HCV NS3-NS4A蛋白酶
公开(公告)号：US07906550B2
公开(公告)日：2011-03-15
申请号：US12026705
申请日：2008-02-06
申请人： Kevin M. Cottrell , John Maxwell , Robert B. Perni , Janos Pitlik
发明人： Kevin M. Cottrell , John Maxwell , Robert B. Perni , Janos Pitlik
IPC分类号： A61K31/4025 , C07D207/30
CPC分类号： C07K5/0804 , A61K31/40 , A61K45/06 , A61K2300/00
摘要： The present invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐。因此，它们通过干扰丙型肝炎病毒的生命周期起作用，并且作为抗病毒剂是有用的。本发明还涉及包含用于离体使用或用于给予HCV感染患者的所述化合物的药学上可接受的组合物以及制备该化合物的方法。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗患者HCV感染的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式